Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Eidos Therapeutics – Linkedin
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease.
Launched in 2016 after years of research supported by Stanford’s SPARK program, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.
myBinderRelated Content
-
At Least Partial Hematological Response After First Cycle of Treatment Predicts Organ Response and Long-term Surviva...AL amyloidosis is a rare plasma cell dys...
-
Proteasome Inhibitors – ASG Webinar 3/13https://www.youtube.com/watch?v=4gUXPbOk...
-
ATTR Treatment Chart – ASG Webinar 7.15.23 – 1/7https://www.youtube.com/watch?v=UcxmPgZ7...
-
Seattle Cancer Care AllianceSeattle Cancer Care Alliance (SCCA) is a...
-
IMiDS, Alkylators & Anti-Fibril Drugs by Dr. Anita D’Souza – ASG Webinar – 2/9https://www.youtube.com/watch?v=vP4wvJq5...
-
Introduction & Discussion: Andromeda Drug Trial (daratumumab) and Related Topicshttps://www.youtube.com/watch?v=PYbsAmtZ...
-
Emerging Advances in the Management of Cardiac AmyloidosisAmyloidosis is a disease in which protei...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
